- Charles B Wilson, director (wilsonc@neuro.ucsf.edu)ab
- a Institute for the Future, Menlo Park, CA 94025-7020, USA
- b Correspondence to: Department of Neurosurgery, University of California at San Francisco, San Francisco, CA 94143-0350, USA
During the next decade diseases requiring medical intervention will be much the same as those being treated today. The site of care may, however, be moved away from the community general hospital to a non-hospital site or to a higher order or specialty hospital at a distance.
With the applications of technological advances, procedures that once were performed in hospitals are now done in free standing facilities, accelerating a trend that began in the United States in the 1980s with the introduction of magnetic resonance imaging, fibreoptic endoscopes and arthroscopes, and ambulatory surgicentres. Just as the discovery and successful treatment of Helicobacter pylori for peptic ulcer replaced a commonly performed operation so new advances will eliminate the need for care once provided by hospitals, and hospitals will become places that treat conditions that cannot be treated in other settings.
Summary points
Pharmaceuticals will replace some procedures and will decrease the need for admission to hospital, and newer vaccines will treat as well as prevent disease
Minimally invasive surgery will reduce hospital stay and promote outpatient operations
Sensors will change central laboratories and intensive care units of today
Digitised images will be accessible to all clinicians
Xenotransplantation from transgenic pigs is ever more likely
Economics and superior outcomes will favour specialty hospitals
Pharmaceuticals
An abundance of new pharmaceuticals will alleviate a wide range of common diseases that account for a large proportion of patients currently admitted to hospital for inpatient care. New pharmaceuticals will reduce the incidence of atherosclerosis, coronary artery disease, and in particular stroke. Other pharmaceutical advances will promote the opening of stenotic arteries and the dissolution of acute thrombi Biotechnology companies are developing products that will prevent, modify, or treat a variety of cancers—breast cancer being one of the first treated.1 2 How significantly pharmaceuticals will affect infectious diseases, and …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
The decline in the breast cancer incidence is 1.2% and it is not significant.
Published 10 February 2012
'twas ever thus
Published 10 February 2012
The value of historic human remains
Published 10 February 2012
In Praise of British Literature
Published 10 February 2012
Is real shared decision making possible?
Published 10 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (7 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (7 responses)
Published 1 Feb 2012
Search for evidence goes on (5 responses)
Published 17 Jan 2012